Dyslipidemia refers to abnormalities in lipids and lipoproteins in the circulation and is a key modifiable risk factor for cardiovascular (CV) disease. The most common lipid abnormalities include elevated levels of LDL-cholesterol and/or triglyceride levels. Statins are firmly established as first-line treatment for most patients with dyslipidemia, owing to their proven CV benefits, physician familiarity with the class, and the increased availability of low-priced generic options. However, a lack of high-quality CV outcomes trial data has weakened physicians’ confidence in many nonstatin drug classes, particularly those agents that lower triglyceride levels. Nonetheless, physicians recognize that many statin-treated patients have residual CV risk and consequently use additional therapies, including the efficacious but expensive proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. This report explores the current U.S. prescribing landscape for dyslipidemia and the factors that influence it.
Do physicians have a preference between Praluent and Repatha? What are the major factors driving/constraining the use of the PCSK9 inhibitor class?
How do drug preferences change at each line of therapy in different reimbursement environments?
What is influencing the prescribing of endocrinologists and cardiologists for dyslipidemia, and how are these factors expected to change?
How do prescribing patterns differ between lipid disorders; which therapies are most popular for the treatment of these different populations?
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that clients can create specific messaging around these treatment dynamics in order to more effectively increase or defend their market position.
Survey of 52 endocrinologists and 51 cardiologists in the United States.
Current Treatment: Physician Insights Dyslipidemia-US
Andrew Frost is a business insights analyst on the Cardiovascular, Metabolic, Renal, and Hematologic Disorders team at DRG, part of Clarivate. In this role, he evaluates the latest primary and secondary research, as well as available commercial information, to forecast the potential of developmental drugs and provide insight on the various dynamics affecting relevant markets. Prior to joining DRG, he was a senior drug analyst at Citeline. He holds a B.Sc. (Honors) degree in pharmacology from King’s College London.